A new T-cell treatment for acute myeloid leukemia after transplant
Official title: Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease
Funded at Marker Therapeutics, INC. · NIH-11042150 · Data updated 2026-11-12
This project explores a new T-cell treatment designed to prevent acute myeloid leukemia from returning in people who have had a stem cell transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Marker Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 15, 2022 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $188,702 |
| NIH project number | 5R01FD007272-03 |
| Project ID | NIH-11042150 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with acute myeloid leukemia who have recently undergone an allogeneic stem cell transplant and still have minimal signs of the disease.
✕Less likely to help
Patients who have not received an allogeneic stem cell transplant or who do not have acute myeloid leukemia would not benefit from this specific treatment.
What this research studies
Acute myeloid leukemia (AML) can sometimes come back after a stem cell transplant, which is a major concern for patients. This new approach uses special T-cells, called MT-401, that are trained to recognize and fight multiple markers on leukemia cells at the same time. These T-cells are made from the same donor who provided the stem cells for the transplant. By targeting several markers, this treatment aims to make it harder for leukemia cells to hide or escape the immune system, offering a new way to keep the cancer from returning.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the risk of AML relapse after a stem cell transplant, improving long-term survival for patients.
How similar studies have gone: While T-cell therapies have shown promise in other cancers, this specific multi-antigen approach for AML after transplant is a novel strategy being tested.
Where this research is happening
-
Marker Therapeutics, INC.
Houston, United States Active
Researchers
- Principal investigator: Vera, Juan Fernando — Marker Therapeutics, INC.
- Study coordinator: Vera, Juan Fernando
Related research
Other NIH-funded projects on the same topics.
-
Targeting early oral GVHD to improve mouth health after stem cell transplant
A study at UW–Madison will explore why some transplant patients develop painful oral GVHD and test ideas to prevent and lessen mouth-related problems.
-
Innate and Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
A liver transplant-focused project investigates how the body’s early and later immune responses affect transplant failure or success after reperfusion.
-
Exercise-based frailty program for people awaiting lung transplants
A tailored exercise and lifestyle program is being tested to reduce frailty and improve outcomes for people waiting for a lung transplant.
-
Diabetes and Donor Tissue in Corneal Transplants
This grant studies whether corneas from donors with diabetes affect the success of Descemet membrane endothelial keratoplasty (DMEK) and what factors predict better or worse outcomes.
-
Microbial clues to diagnose and predict infections in kidney transplant patients
A patient-focused project will look for microbial biomarkers in stool, blood, and urine to help doctors predict and diagnose infections in people who have had a kidney transplant.
-
Medicare Advantage and Transplant Access for Rural and Vulnerable Communities
Aimed at understanding how Medicare Advantage affects early steps to kidney transplant for adults in rural or socioeconomically challenged groups.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.